Abstract:Cancer cells are characterized by aberrant signal transduction and cell cycle control pathways that lead to unchecked cell proliferation. Uncontrolled cancer cell proliferation, as well as immune suppressive macrophage proliferation, contribute to tumor growth and spread. Effort to suppress tumor cell growth using Inhibitors of PI3K or MEK signaling pathways can initially inhibit tumor growth, but resistance develops due to upregulation of the alternative pathway. We identified a novel series of allosteric tyrosine kinase receptor inhibitors that induce synthetic lethality in AML, lung carcinoma, pancreatic carcinoma, and other tumor cells and in proliferating macrophages in vitro and in vivo by simultaneously inhibiting cMyc and Tor and activating the stress activated kinase JNK, leading to p53 mediated cell cycle arrest. Select kinase inhibitors with a unique positioning of a single side chain inhibited CDK8/19 and thereby Myc while stimulating phosphorylation and activation of JNK and p38. JNK activation promoted sustained ATF-2 and cJun-mediated p53 and Chk1/Chk2 activation, thereby promoting cell cycle arrest in G2/M and ultimately, apoptosis. These inhibitors potently suppressed tumor growth in vivo by halting both tumor cell and macrophage proliferation in G2/M. They synergized with anti-PD-1 and anti-CTLA-4 and led to tumor eradication and immunological memory formation. These studies identify novel allosteric inhibitors with potent synthetically lethal anti-tumor activity. Citation Format: Hui Chen, Jason Rivera, Marc Paradise, Zihan Xu, Giuliana Mognol, Judith Varner. A new cancer therapy strategy: Synthetic lethality induced by inhibition of mTOR and cMYC and JNK activation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 7577.

Cyclin-dependent kinases-based synthetic lethality: Evidence, concept, and strategy

Synthetic Lethality: a Promising Therapeutic Strategy for Hepatocellular Carcinoma.

Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation

Synthetic Lethality in Drug Development: the Dawn is Coming

Synthetic Lethality in Personalized Cancer Therapy

The biological essence of synthetic lethality: Bringing new opportunities for cancer therapy

Synthetic Lethal Interactions in Cancer Therapy

The power and the promise of synthetic lethality for clinical application in cancer treatment

Synthetic lethal strategies for the development of cancer therapeutics

Synthetic Approaches and Clinical Application of Representative Small-Molecule Inhibitors of Cyclin-Dependent Kinase for Cancer Therapy

Synthetic lethality as an engine for cancer drug target discovery

The tumor therapy landscape of synthetic lethality

Abstract 7577: A new cancer therapy strategy: Synthetic lethality induced by inhibition of mTOR and cMYC and JNK activation

Unleashing the Power of Synthetic Lethality: Augmenting Treatment Efficacy Through Synergistic Integration with Chemotherapy Drugs

Research Progress for the Development of Anti-Tumor Drugs Based on Synthetic Lethality

Systematic Analysis of Cancer-Specific Synthetic Lethal Interactions Provides Insight into Personalized Anticancer Therapy.

Epigenetic Based Synthetic Lethal Strategies in Human Cancers

Collateral Lethality: A Unique Type of Synthetic Lethality in Cancers

Targeting cell cycle regulation via the G2-M checkpoint for synthetic lethality in melanoma

An update on small molecule compounds targeting synthetic lethality for cancer therapy

Complex synthetic lethality in cancer